Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera/Rituxan in Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
NCT01998893Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 1997
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in follicular lymphoma (FL), sponsored by Roche. Started Jan 1997; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01998893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998893.